ARTICLE | Company News

Endo, EpiCept deal

August 17, 2015 7:00 AM UTC

The companies terminated a 2003 deal granting Endo exclusive, worldwide rights to commercialize LidoPain BP. EpiCept, now Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP, New York, N.Y.), will transfer back to Endo patents covering topical lidocaine for acute and chronic back pain, and Endo will grant Immune a royalty-free, non-exclusive license to the patents. ...